Fifth Third Bancorp Buys 42,976 Shares of ICU Medical, Inc. $ICUI

Fifth Third Bancorp lifted its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 26,365.6% during the first quarter, Holdings Channel reports. The fund owned 43,139 shares of the medical instruments supplier’s stock after buying an additional 42,976 shares during the quarter. Fifth Third Bancorp’s holdings in ICU Medical were worth $5,571,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ICUI. Millennium Management LLC raised its holdings in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after purchasing an additional 690,694 shares during the period. Norges Bank bought a new stake in ICU Medical in the 4th quarter valued at about $58,083,000. Thrivent Financial for Lutherans raised its stake in ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after buying an additional 285,648 shares during the period. UBS Group AG boosted its holdings in ICU Medical by 239.8% in the third quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock worth $46,371,000 after acquiring an additional 272,782 shares in the last quarter. Finally, Brown Advisory Inc. bought a new position in ICU Medical in the fourth quarter worth approximately $32,445,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ICUI shares. Needham & Company LLC upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 27th. BTIG Research started coverage on shares of ICU Medical in a research note on Monday, June 15th. They set a “buy” rating and a $170.00 price target for the company. Piper Sandler lowered their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Zacks Research upgraded shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Finally, Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, ICU Medical currently has a consensus rating of “Buy” and a consensus target price of $168.40.

Insider Activity at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the transaction, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company’s stock.

ICU Medical Trading Down 2.9%

NASDAQ:ICUI opened at $157.51 on Friday. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $162.85. The firm has a 50-day moving average price of $140.76 and a two-hundred day moving average price of $139.26. The firm has a market cap of $3.94 billion, a price-to-earnings ratio of 85.14, a price-to-earnings-growth ratio of 2.27 and a beta of 0.76. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. During the same period last year, the company posted $1.72 earnings per share. ICU Medical’s quarterly revenue was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, equities analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.